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Abstract
Background: The objective of this study was to estimate the effect of male circumcision (MC) on HIV acquisition 
estimated using HIV incidence assays and to compare it to the effect measured by survival analysis.
Methods: We used samples collected during the MC randomized controlled trial (ANRS-1265) conducted in Orange 
Farm (South Africa) among men aged 18 to 24. Among the 2946 samples collected at the last follow-up visit, 194 HIV-
positive samples were tested using two incidence assays: Calypte HIV-EIA (BED) and an avidity assay based on the 
BioRad HIV1/2+O EIA (AI). The results of the assays were also combined (BED-AI). The samples included the 124 
participants (4.2% of total) who were HIV-positive at randomization. The protective effect was calculated as one minus 
the intention-to-treat incidence rate ratio in an uncorrected manner and with correction for misclassifications, with 
simple theoretical formulae. Theoretical calculations showed that the uncorrected intention-to-treat effect was 
approximately  independent of the value of the incidence assay window period and was the ratio of the number tested 
recent seroconverters divided by the number tested HIV-negative between the randomization groups. We used cut-off 
values ranging from 0.325 to 2.27 for BED, 31.6 to 96 for AI and 0.325-31.6 to 1.89-96 for BED-AI. Effects were corrected 
for long-term specificity using a previously published formula. 95% Confidence intervals (CI) were estimated by 
bootstrap resampling.
Results: With the highest cut-off values, the uncorrected protective effects evaluated by BED, AI and BED-AI were 50% 
(95%CI: 27% to 66%), 50% (21% to 69%) and 63% (36% to 81%). The corrections for misclassifications were lower than 
50% of the number of tested recent. The corrected effects were 53% (30% to 70%), 55% (25% to 77%) and 67% (38% to 
86%), slightly higher than the corresponding uncorrected values. These values were consistent with the previously 
reported protective effect of 60% (34% to 76%) obtained with survival analysis.
Conclusions: HIV incidence assays may be employed to assess the effect of interventions using cross-sectional data.
Background
Since the first detuned enzyme immunoassay (EIA) to
detect recent HIV seroconversion was described in 1998
[1], there has been great interest in the application of lab-
oratory methods to measure HIV incidence in cross-sec-
tional samples. Currently, the most widely used incidence
assay is the BED capture assay [2]. HIV incidence estima-
t i o n  is  i n cr e as i n g l y  be i n g  i n c o rpo r a t ed  i n t o  H IV / A IDS
surveillance activities in both resource-rich and develop-
ing countries [3]. In 2005, the UNAIDS Reference Group
on Estimates, Modeling and Projections issued a caution-
ary statement about using BED to estimate HIV incidence
and called for the development of additional laboratory
and modeling methodologies [4].
The ability to reliably measure HIV incidence using
cross-sectional data has vast public health importance in
HIV surveillance as well as in the preparation of cohorts
for vaccine, microbicide, pre exposure prophylaxis or
other potential HIV prevention studies. Reliable cross-
sectional HIV incidence measures would reduce the need
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to recruit and maintain large and costly longitudinal
cohorts. However, two of the current challenges in using
HIV incidence assays to characterize HIV incidence are
knowledge of the incidence assay window period (i.e.
time interval during which individuals are characterized
as recently infected) and misclassifications.
Another potential interest of HIV incidence testing is to
conduct risk factor analysis on HIV incidence and to
evaluate the effect of interventions aiming to reduce the
spread of HIV. Here, the question is to estimate the ratio
of incidence rates among subgroups of a given popula-
tion. The objective of this study was to demonstrate the
utility of HIV incidence assays in estimating the effect of
an intervention. This was achieved by using two inci-
dence assays applied to samples collected during the male
circumcision (MC) randomized controlled trial (ANRS-
1265) conducted in Orange Farm (Gauteng Province,
South Africa) [5], and by comparing the results with
those already published and obtained by classical survival
analysis conducted on the same data.
Methods
Longitudinal data
The technical details of the Orange Farm MC trial
(ANRS-1265) have been published elsewhere [5]. Briefly,
male participants, aged 18 to 24, were recruited from the
general population of the township of Orange Farm and
followed up for 21 months. The recruitment, randomiza-
tion between intervention and control groups, and fol-
low-up were conducted independently of the HIV status
of participants. At inclusion after providing written
informed consent and during each follow-up visit V2, V3
and V4 at about 3, 12 and 21 months, a blood sample was
obtained. The data used in the current study includes 596
additional follow-up visits, which were collected after the
database used to report the results of the trial on HIV
incidence [5] was locked, as described elsewhere [6]. The
research protocol was reviewed and approved by the Uni-
versity of Witwatersrand Human Research Ethics Com-
mittee (Medical) on February 22nd, 2002 (protocol study
no. M020104).
Laboratory methods
All blood samples collected were tested for HIV using
three enzyme immunoassays (EIA) as described previ-
ously [5]. Blood samples testing positive for HIV were
retested using two HIV incidence assays: Calypte HIV-1
BED Incidence EIA (BED, Calypte Biomedical Corpora-
tion, Lake Oswego, Oregon, USA), and an avidity assay
based on the BioRad HIV 1/2+O EIA (Avidity, Bio-Rad
Laboratories, Redmond, Washington, USA). The BED
assay was performed according to the manufacturer's
protocol and gave a normalized optical density ranging
between 0.034 to 3.9.
The avidity assay was performed as previously
described [7]. Briefly, samples, placed in two consecutive
wells, were diluted 1:10 and incubated at 4°C for 30 min-
utes for the initial antibody binding step. One of the wells
for each sample was then incubated with 0.1M Dieth-
ylamine for 30 minutes at 37°C for the chaotropic disas-
sociation step, while the other well was incubated with
wash buffer. The avidity index (AI) was calculated as the
optical density (OD) of the treated well divided by the OD
of the untreated well multiplied by 100. AI varied from
5.7 to 131.6. Values greater than 100 were reported as
100. There were six individual time points with untreated
avidity OD values lower than the avidity OD threshold
(0.1). These individuals were considered as recently
infected.
Data analysis
The details of the methods used are given in the Addi-
tional file 1.
Samples yielding a result lower or equal to the cut-off
value for an incidence assay were reported as "tested
recent seroconverters". All other HIV-positive partici-
pants were reported as "tested long-term seroconverters"
for the assay. The two assays were also used in combina-
tion (BED-AI). In this case, participants with both BED
and AI results lower or equal to the corresponding cut-off
values were reported as "tested recent seroconverters".
Uncorrected results were calculated without correction
for misclassifications. Corrected results were calculated
by correcting for misclassifications. We used the conven-
tional cut-off values of 0.80 for BED and 40 for AI. We
also varied the cut-off values in order to obtain window
periods of 3, 6, 9, 12, 15 and 18 months for both assays
from samples of the 67 participants who became HIV
positive during follow-up.
Using the results given by the two assays, we calculated
the window periods with conventional cut-offs for each
assay, as well as the cut-off values for the two assays in
order to obtain predetermined window periods of 3, 6, 9,
12, 15 and 18 months. We statistically compared the
results (recent/not recent) given by the BED and the AI
assays when using the conventional cut-off values. We
estimated the window periods when combining the two
assays. We calculated the proportion of false long-term
seroconverters and the proportion of false recent sero-
converters. For each individual, we assessed the varia-
tions of the assay results over time and, finally, the effect
of MC on HIV incidence, which is the main outcome of
this study. Confidence intervals were obtained using the
bootstrap method with 1000 repetitions, except for the
confidence intervals of proportion calculated using
Bayesian estimation [8]. As shown in Additional file 1, the
uncorrected and corrected incidence rate ratios (IRR) at aFiamma et al. BMC Infectious Diseases 2010, 10:137
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given point in time were calculated using the following
formulae:
and
in which NTR is the number of tested recent serocon-
verters, N- is the number of HIV negative participants, N+
is the number of HIV positive participants and is the
long-term specificity. The uncorrected IRR is indepen-
dent of the window period. The corrected IRR depends
on the long-term specificity, which varies with the win-
dow period (see below).
Among the 3153 trial participants who had a HIV test
at inclusion and at least one HIV test during follow-up,
2946 participants were tested for HIV, BED and AI at V4.
Data from these participants were used to calculate the
effect of the intervention. Among them, 194 tested HIV-
positive at V4, 124 having tested HIV-positive at random-
ization and 70 becoming HIV-positive during follow-up.
Among the 3153 participants, 72 participants became
HIV-positive during follow-up but five had a missing fol-
low-up visit immediately preceding the follow-up visit
when they tested HIV-positive for the first time. The
remaining 67 participants were used to calculate the
window periods corresponding to specified cut-off values
and to calculate cut-off values corresponding to specified
window periods.
Results
Window periods with conventional cut-offs
Using the 67 participants who became HIV positive dur-
ing follow-up, the number of tested recent seroconverters
was found to be 47 for BED and 37 for AI when using the
conventional cut-off values. The corresponding window
periods were 185 days (6.0 months; 95% CI: 146 to 227)
and 135 days (4.4 months; 95% CI: 101 to 176), respec-
tively.
Cut-offs for various predetermined window periods
Using the same 67 participants who became HIV positive
during follow-up, the cut-off values corresponding to
predetermined window periods of 3, 6, 9, 12, 15 and 18
months for each of the two assays were calculated and are
given in Table 1.
Window periods when combining the two assays
The incidence assay window periods obtained when com-
bining the two assays are indicated in Table 2 for each of
the five pairs of cut-of values. As expected, because of the
discordance between the results given by the two tests,
the window period for each pair was slightly shorter than
the corresponding window period for each test taken
individually.
False long-term seroconverters
The proportion of false long-term seroconverters for
each test used separately and in combination are indi-
cated in Tables 3 and 4. It appears that this proportion,
and consequently the sensitivity, was fairly independent
of the cut-off values; sensitivity stayed above 75% when
the assays were used independently or in combination.
False recent seroconverters
The observed proportion of false recent seroconverters
for each test used separately and in combination is indi-
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Table 1: Cut-off values for BED and AI incidence assays for predetermined incidence assay window periods
Window period 3 m
(91.5 d)
6 m
(183 d)
9 m
(274 d)
12 m
(366 d)
15 m
(457 d)
18 m
(549 d)
BED Cut-off 0.325 0.733 0.90 1.51 1.89 2.27
95% CI 0.21 to 0.41 0.49 to 1.14 0.66 to 1.50 0.88 to 1.89 1.58 to 2.17 2.02 to 2.64
AI Cut-off 31.6 80.5 90.0 94.0 96.0 NC
95% CI 20.6 to 37.0 42.9 to 90.1 84.0 to 94.0 90.0 to 97.5 94.0 to 99.7
m: months
d: days
AI: avidity index
NC: Not calculable
CI: Confidence intervalFiamma et al. BMC Infectious Diseases 2010, 10:137
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cated in Tables 3 and 4. This proportion increased with
cut-off values, implying that long-term specificity
decreases with increased cut-off values. The proportion
of false recent seroconverters was similar between assays
when compared for the same window period. Comparing
the proportion obtained when combining the two assays
with the assays used individually is meaningful because of
the difference between window periods. Nevertheless,
Tables 3 and 4 show that this proportion was slightly
lower when combining the two assays. For example com-
bining BED and AI with a window period of 268 days
gave a proportion of false recent seroconverters of 4.8%,
whereas using both BED and AI separately for a similar
window period (274 days) gave a result of 6.4% and 8.8%,
respectively. When using the conventional cut-off value
for BED, the long-term specificity was 93.6% (1 minus
6.4%).
Individual response of test results over time
The average (standard deviation) slope of the variation of
assay results with time was 0.023 (0.027) per month for
BED and 0.47 (1.08) per month for AI. The proportion of
individuals with values given by the assays decreasing
with time (i.e.: negative slope) was 15/104 (0.14; 95% CI:
0.086 to 0.22) for BED and 35/104 (0.34; 95% CI: 0.25 to
0.43) for AI. The proportion of individuals having values
given by the two tests decreasing was 9/104 (0.087; 95%
CI: 0.043 to 0.15). The proportion of those having values
given by at least one test decreasing was 43/104 (0.41;
95% CI: 0.32 to 0.51).
Comparison of results given by the BED and AI assays, and 
with HIV testing
We compared those tested recent seroconverters by the
BED assay with those identified by AI when using the cut-
off value of 0.73 for the BED assay and 80.5 for AI, which
both correspond to a window period of six months.
Among all 194 participants testing HIV-positive at V4,
the BED assay and AI detected 39 and 29 seroconverters,
respectively. Of these, 25 were tested recent for both
assays, 151 were tested not recent for both assays, 14
were tested recent with BED and tested not recent with
AI, and four were tested recent with AI and tested not
recent with BED. The difference was statistically signifi-
cant (p = 0.031; McNemar's test) and the kappa was 0.68
(95% CI: 0.54 to 0.82) indicating a substantial agreement
between the two assays.
The comparison between the results given by the BED
a n d  A I  a s s a y s  w i t h  o b s e r v e d  H I V  i n c i d e n c e  c a s e s
obtained from HIV testing is given in Table 5. This table
shows that the agreement was moderate  for a window
period of nine months and became fair for window peri-
ods of 12 and 18 months. This table shows that the overall
specificity decreases when the window period increases.
Effect of MC on HIV incidence
We used the 2946 participants with HIV data at V4.
Among these participants, 124 (4.2%) were HIV-positive
at randomization, 194 were HIV-positive at V4 (114 in
the intervention group and 80 in the control group) and
2752 were HIV-negative at V4 (1412 in the intervention
group and 1340 in the control group). Using the samples
collected at this fourth visit, the uncorrected and cor-
rected protective effects of MC derived when using BED,
AI and BED-AI for the six window periods are presented
in Tables 3 and 4, when they were calculable. These tables
indicate the number of tested recent seroconverters
observed for each assay per intervention group, which, as
expected, increased with the cut-off values. These tables
also indicate the relative correction applied to the num-
ber of tested recent seroconverters to estimate the real
number of recent seroconverters.
When the cut-off values were low, the small number of
tested recent seroconverters led to lower statistical
power, larger confidence intervals and imprecise estima-
tion of the effect of MC on HIV incidence. When the cut-
off values were increased, the uncorrected IRR tended to
become closer to the HIV prevalence ratio which was
0.684 (80/114), corresponding to an effect of the inter-
vention of 31.6%.
Tables 3 and 4 show that the corrections for misclassifi-
cations were in total always lower than 50% of the num-
ber of tested recent seroconverters. The highest cut-off
values used for BED, AI and BED-AI were 2.27, 96 and
1.89-96, respectively. For each of these values, we
obtained a total number of tested recent seroconverters
of 121, 95 and 57, which in two cases was higher than the
number (70) of participants who became HIV positive
Table 2: Incidence assay window periods obtained when combining BED and AI incidence assays for various pairs of cut-
off values
BED - AI Cut-off 0.325 - 31.6 0.733 - 80.5 0.90 - 90.0 1.51 - 94.0 1.89 - 96.0
Window period 65.9 d 159 d 213 d 268 d 300 d
95% CI in days 45.3 to 93.5 122 to 211 163 to 264 211 to 352 234 to 388
d: days
AI: avidity index
CI: Confidence intervalFiamma et al. BMC Infectious Diseases 2010, 10:137
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Table 3: False recent seroconverters and protective effect of MC on HIV incidence as calculated using BED and AI 
separately
BED
Cut-off 0.325 0.733 0.900 1.51 1.89 2.27
Window period 3m (91.5d) 6m (183d) 9m (274d) 12m (366d) 15m (457d) 18m (549d)
False LTS (%) 0/3 (0) 1/12 (8.3) 5/21 (23.8) 5/32 (16) 2/34 (5.9) 3/47 (6.4)
95% CI 0 to 0.53 0.5 to 32 9.6 to 44 6 to 30 1 to 17 2 to 16
Observed false RS (%) 1/124 (0.8) 6/124 (4.8) 8/124 (6.5) NC NC NC
95% CI 0.05 to 3.8 1.9 to 9.6 3 to 12
1Calculated false RS (%) 2.1 4.3 6.4 8.5 10.7 12.8
Tested RSs
Intervention - Control 6 - 10 12 - 27 15-30 23 - 48 33 - 62 42 - 79
Uncorrected effect (%) 43 58 53 55 49 50
95% CI -57 to 84 19 to 80 13 to 77 26 to 75 23 to 67 27 to 66
2Correction
Intervention (%) 28 29 34 30 26 24
C o n t r o l  ( % ) 2 4 1 8 2 42 02 01 8
T o t a l  ( % ) 2 5 2 1 2 82 32 22 1
C o r r e c t e d  e f f e c t  ( % ) 4 6 6 3 5 96 05 35 3
95% CI NC 22 to 88 9 to 86 25 to 80 25 to 73 30 to 70
AI
Cut-off 31.6 80.5 90.0 94.0 96.0 NC
Window period 3m (91.5d) 6m (183d) 9m (274d) 12m (366d) 15m (457d) 18m (549d)
False LTS (%) 0/3 (0) 1/12 (8.3) 3/21 (14) 4/32 (13) 4/34 (12) NC
95% CI 0 to 53 0.5 to 32 4 to 33 4 to 27 3.8 to 25
Observed false RS (%) 0/124 (0) 3/124 (2.4) 15/124 (12) NC NC NC
95% CI 0 to 2.4 0.6 to 6.2 7 to 19
1Calculated false RS (%) 2.9 5.9 8.8 11.8 14.7 NC
Tested RSs NC
Intervention - Control 3 - 11 10 - 19 18-31 26 - 44 33 - 62
Uncorrected effect (%) 74 50 45 44 50 NC
95% CI 19 to 100 -6 to 78 3 to 72 17 to 71 21 to 69
2Correction NC
Intervention (%) 77 47 39 36 36
C o n t r o l  ( % ) 3 0 3 5 3 23 12 7
T o t a l  ( % ) 4 0 3 9 3 53 33 0
C o r r e c t e d  e f f e c t  ( % ) 9 2 5 9 5 04 95 5N C
95% CI 14 to 100 -14 to 100 -13 to 83 4 to 78 25 to 77
LTS: Long-term seroconverters
RS: Recent seroconverters
m: months
d: days
AI: Avidity index
NC: Not calculable
CI: Confidence interval
1Estimated by linear regression (see Additional file 1)
2Correction for intervention and control = [NHIV+(1-False RS)]/Ntested recentFiamma et al. BMC Infectious Diseases 2010, 10:137
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during the follow-up period. These cut-off values corre-
sponded to uncorrected effects of the intervention for
BED, AI and BED-AI of 50%, 50% and 63%, and corre-
sponding corrected effects of 53%, 55% and 67%. These
values obtained for the highest values of the cut-off are in
reasonable agreement with the value of 60% (95% CI: 34%
to 76%) obtained by survival analysis applied to the full
dataset [5].
When recalculating the effect using only the 2684 par-
ticipants who were HIV-negative at V3 and were followed
up between V3 and V4, we obtained, using survival analy-
sis, a HIV incidence rate of 0.010/person-year (py) (10/
989.8/py among the intervention group and 0.026/py (25/
965.2/py) among the control group. These incidence rates
led to a protective effect of 61.0% (95% CI: 21.0% to
82.7%). The uncorrected and corrected effects obtained
for BED, AI and BED-AI with cut-off values of 0.900, 90.0
and 1.51-94.0, which corresponded to window periods
similar to the period between V3 and V4 are indicated in
Tables 3 and 4. These values are in reasonable agreement
with the value obtained by survival analysis (see above).
When considering the results obtained for the various
window periods, it can be noted that a) the uncorrected
effects of the intervention are always lower than the cor-
responding corrected effects, and b) the results tend to
become more significant as the cut-off value is increased.
Tables 3 and 4 do not provide evident argument for pre-
ferring one assay over the other, and show that using the
two assays in combination is not obviously more advanta-
geous than using the assays independently. However, it
can be noted that the BED assay allows the use of a cut-off
value corresponding to a window period longer than the
longest window period given by the AI assay.
Discussion
Using a longitudinal dataset obtained during the first MC
randomized controlled trial [5], we were able to demon-
strate for the first time that the effect of the intervention
could have been approximately estimated by HIV inci-
dence testing applied to blood samples collected at the
final follow-up visit. This result was obtained despite the
presence of a substantial proportion of individuals who
were HIV-positive at recruitment. Such results imply that
HIV interventions may be assessed using HIV incidence
assays on samples obtained from a cross-sectional survey
by calculating incidence rate ratios. In addition, the
method we have used is relatively simple because it does
not require the precise knowledge of the window period.
This study has several limitations. It is known that
those on antiretroviral treatment should be excluded
from BED testing to improve the predictive value of
detecting recent infections [9,10]. This was not done in
the present study because such information was not
available. However, it is likely that only a very small num-
Table 4: False recent seroconverters and protective effect of MC on HIV incidence as calculated using BED and AI in 
combination
BED-AI
BED - AI Cut-off 0.325 - 31.6 0.733 - 80.5 0.900 - 90.0 1.51 - 94.0 1.89 - 96.0 NC
Window period 65.9d 159d 213d 268d 300d NC
False LTS (%) NC 1/9 (11) 1/13 (7.7) 2/16 (13) 3/27 (11) NC
95% CI 1 to 40 0.4 to 30 2 to 33 3 to 26
Observed false RS (%) 0/124 (0) 2/124 (1.6) 2/124 (1.6) 6/124 (4.8) NC NC
95% CI 0 to 2.4 0.25 to 5.0 0.3 to 5 1.9 to 9.6
1Calculated false RS (%) 0.9 2.1 2.7 3.5 3.9 NC
Tested RSs NC
Intervention - Control 2 - 7 8 - 17 9-21 11 - 30 16 - 41
Uncorrected effect (%) 73 55 59 65 63 NC
95% CI NC -1 to 84 8 to 84 33 to 85 36 to 81
2Correction NC
Intervention (%) 36 21 24 25 20
C o n t r o l  ( % ) 1 51 41 51 3 1 1
T o t a l  ( % ) 1 91 61 71 7 1 3
C o r r e c t e d  e f f e c t  ( % ) 8 05 96 47 0 6 7 N C
95% CI NC -2 to 93 6 to 92 39 to 90 38 to 86
See table caption of Table 3Fiamma et al. BMC Infectious Diseases 2010, 10:137
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Table 5: Comparison of the results given by the BED and the AI assays with observed HIV incidence cases obtained from 
HIV testing
Visit A
L a b e l V 1V 3V 1V 2
HIV positive cases 127 148 124 124
H I V  n e g a t i v e  c a s e s 1 13 53 25 6
Visit B
L a b e l V 2V 4V 3V 4
HIV positive cases 138 183 156 180
1HIV negative cases 0 0 0 0
From visit A to visit B
Average duration 3.6 m 8.8 m 12.6 m 18.0 m
HIV incident cases 11 35 32 56
BED
Cut-off 0.325 0.90 1.51 2.27
Window period 3.0 m 9.0 m 12.0 m 18.0 m
Tested recent 12 43 54 110
Tested recent not incident case 6 25 21 53
Tested recent and not incident case 6 18 33 57
Not tested recent and incident cases 5 10 11 3
Kappa statistics [95% CI] 0.64 [0.41 to 0.81] 0.55 [0.40 to 0.69] 0.31 [0.16 to 0.46] 0.39 [0.26 to 0.51]
Sensitivity (%) [95% CI] 55 [28 to 79] 71 [56 to 84] 66 [49 to 80] 95 [87 to 99]
Specificity (%) [95% CI] 95 [91 to 98] 88 [82 to 92] 73 [65 to 81] 54 [45 to 63]
AV
Cut-off 31.6 90 94 NC
Window period 3.0 m 9.0 m 12.0 m
Tested recent 11 49 44
Tested recent and incident case 8 28 20
Tested recent and not incident case 3 21 24
Not tested recent and incident cases 3 7 12
Kappa statistics [95% CI] 0.48 [0.31 to 0.64] 0.57 [0.43 to 0.71] 0.38 [0.23 to 0.53]
Sensitivity (%) [95% CI] 73 [45 to 92] 80 [65 to 91] 63 [46 to 78]
Specificity (%) [95% CI] 98 [94 to 99] 86 [79 to 91] 81 [73 to 87]
BED-AI
Cut-off 20.40 - 41 1.51 - 94 NC NC
Window period 9.0 m 8.8 m
Tested recent 10 38
Tested recent and incident case 7 27
Tested recent and not incident case 3 11
Not tested recent and incident cases 4 8
Kappa statistics [95% CI] 0.70 [0.54 to 0.87] 0.68 [0.53 to 0.82]
Sensitivity (%) [95% CI] 64 [36 to 86] 77 [62 to 89]
Specificity (%) [95% CI] 98 [94 to 99] 93 [88 to 96]
m: month
CI: Confidence interval
NC: Not calculable
AI: Avidity index
1For this analysis, the data was reduced to those being HIV positive at V4
2Obtained by linear interpolation from the data presented in Table 2Fiamma et al. BMC Infectious Diseases 2010, 10:137
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ber of participants were receiving anti-retroviral (ARV)
therapy because, in contrast with the current situation in
this community, ARVs were not widely available during
the course of the study. Moreover, because only a few par-
ticipants were aware of their HIV status and because of
their young age, the proportion of HIV-positive partici-
pants eligible for ARVs is expected to have been low.
Another limitation is that the correction required the
knowledge of long-term specificity. This value was calcu-
lated using the same data set and thus was not indepen-
dent. Finally, this study provides some information about
the comparative behavior of the assays when used on the
same samples but did not have the power to formally
compare the results given by these assays a) between
them and b) with the results obtained when using sur-
vival analysis applied to the exact seroconversion data.
This lack of power is evidenced by the wide confidence
intervals of the estimated effects. Further studies are
needed to compare these assays and to evaluate the bene-
fit of using them in combination.
To our knowledge, the Orange Farm MC study is the
only randomized controlled trial to have recruited and
followed participants irrespective of their HIV status.
Hence, the results obtained in this study may be difficult
to reproduce. However, this allowed us to simulate what
would happen in cross-sectional studies where HIV posi-
tive participants are not excluded.
Our results were obtained from young men (18 to 24
years old) in an area of relatively high HIV prevalence.
According to the 2008 South African National HIV Prev-
alence, Incidence, Behavior and Communication Survey,
HIV prevalence among young men 20 to 24 was 5.1% and
21.1% among women of the same age [11]. Among young
men in the Orange Farm area, as in South Africa, HIV
prevalence is relatively low and HIV incidence is high.
These characteristics may have facilitated this study.
With higher HIV prevalence, the impact of corrections
for misclassifications would have been higher and may
have reduced the precision of the estimations [12,13].
However, we think that the use of HIV incidence testing
to assess the effect of interventions through HIV inci-
dence rate ratios can be used as long as the sample size is
adapted to the long-term specificity of the assays and
when the cut-off values are such that the corrections for
misclassifications are kept reasonably low.
In this study, we obtained similar results for each assay,
and combining the assays did not noticeably improve the
results. A study conducted using blood samples collected
among female sex workers in the Dominican Republic
found a good correlation between BED and AI methods
(100%; kappa = 1.0) using an unweighted kappa statistic
in pairwise comparisons [14]. Our study showed a lower
agreement between the two assays.
The choice of the cut-off values is important to obtain a
precise estimate of the incidence rate ratio. The cut-off
values must be high enough to yield a high number of
tested recent seroconverters and thus a small confidence
interval, but low enough to yield a low number of false
recent seroconverters and thus a small correction for
misclassifications. The cut-off values should also be high
enough to correspond to a reasonably large window
period, in order to smooth the measured effect on an ade-
quately large time interval. Our study shows that cut-off
values corresponding to window periods of 12-18 months
can be used in this population of young men.
The long-term false-positive ratio given by the BED
assay with a cut-off value of 0.80 was estimated to be
0.0169 among a sample of 4869 South African individuals
[15]. Our estimate was slightly higher with a similar cut-
off value. It was closer to the value of 0.052 estimated
from plasma samples collected in Zimbabwe [16].
Some studies have highlighted the difficulties of using
incidence testing for estimating HIV incidence [17-19].
The first issue is the need to know the window period
corresponding to a given assay cut-off. The second is that
the misclassification may vary with factors such as age,
gender, HIV subtype, ARV coverage, stage of the epi-
demic, population and region [17]. The interest in correc-
tion procedures that have been proposed to correct HIV
incidence rates derived from cross-sectional surveys of
biomarkers has been discussed [13,20]. In contrast, some
studies found a good concordance in the classification of
recent HIV-1 infections between incidence testing and in
the correlates of acquisition of infection [21]. HIV inci-
dence testing has been used in some studies to assess
trends and risk factors for HIV incidence [22,23]. The
value of the window period for the BED assay obtained in
this study using a cut-off value of 0.8 was close to the
value of 187 days estimated using longitudinal data col-
lected among 85 South-African women [16].
In the current study, we did not need to estimate HIV
incidence nor did we need to know the window period
precisely. Indeed, the effect of the intervention was
assessed through an incidence rate ratio, which can be
estimated using incidence testing without knowing the
value of the window period, as shown by the uncorrected
formula that we have used. This formula depends mainly
on the estimation of the ratio of the number of recent
seroconverters between the intervention and control
groups. The use of the corrected formula required the
knowledge of the long-term specificity, which varies with
the window period. Because this term was used to calcu-
late a correction, which can be substantial, a good estima-
tion of its numerical value is required.
The correction that we have used is based on a formula
published by McDougall and colleagues [24]. This for-
mula assumes that, among those who survive, the num-Fiamma et al. BMC Infectious Diseases 2010, 10:137
http://www.biomedcentral.com/1471-2334/10/137
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ber of HIV infections having occurred is the same during
the window period than in the period preceding the win-
dow period and of the same duration. In a situation where
HIV prevalence is rising and when using a window period
longer than conventionally used, this assumption may no
longer hold.
Vaccine, microbicide, pre exposure prophylaxis or
other potential HIV prevention or intervention studies
would benefit from using more precise and recent com-
parison of incidences through the estimation of incidence
rate ratios derived from cross-sectional surveys. Cross-
sectional HIV incidence rate ratio estimations would
reduce the need to recruit large longitudinal cohorts,
which are costly, and may suffer from recruitment bias.
Using cut-off values higher than conventionally employed
and appropriate age-groups, when possible, would obvi-
ate the need to recruit large numbers of people such as
what was previously done in Uganda for example, where a
cross-sectional survey of more than 21 000 people was
evaluated with a BED cut-off value of 0.4 [25].
Estimating the effect of an intervention by assessing the
incidence rate ratio is important in HIV prevention
research. Conducting randomized controlled trials and
following up HIV-negative participants to measure HIV
incidence among various groups and then comparing
HIV incidence by calculating incidence rate ratio is not
always feasible, sometimes for ethical reasons. For exam-
ple, in conducting intervention studies, the effect of the
intervention may not be assessed using longitudinal
cohorts but could only be measurable using cross-sec-
tional studies. The current MC roll-out study in Orange
Farm in which MC is being made available to the commu-
nity (ANRS-12126) with the objective of testing the effect
of MC on HIV incidence in 'real life' is an example. The
results of this study show that this effect may well be
assessed by conducting a post-intervention cross-sec-
tional study. One additional advantage is that cross-sec-
tional respondents are more likely to be representative of
the population. Such characteristics are difficult to obtain
when recruiting a cohort. Another example is Project
Accept (National Institute of Mental Health, HPTN 043),
a community randomized trial providing community
mobilization, mobile HIV voluntary counseling and test-
ing and comprehensive post-test supportive services. In
this trial, the outcome will be assessed using HIV inci-
dence assays to estimate HIV incidence rate ratio in order
to compare control and intervention communities.
Conclusions
HIV incidence assays may be employed to assess the
effect of interventions using cross-sectional data.
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